Navigation Links
ULURU Inc. Reports Third Quarter 2011 Financial Results
Date:11/15/2011

ADDISON, Texas, Nov. 15, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU) today announced its financial results for the third quarter ended September 30, 2011.

For the third quarter of 2011, the Company reported a net loss of $1.0 million, or $0.18 per share, compared with a net loss of $1.2 million, or $0.22 per share, for the same period last year.  For the nine months ended September 30, 2011, the Company reported a net loss of $3.2 million, or $0.55 per share, compared with a net loss of $4.7 million, or $0.87 per share, for the same period last year.  

Commenting on the financial results Kerry P. Gray, President and CEO, stated, "Revenue was lower than projected as a major distributor order of approximately $200,000 was not billed until October due to a production delay.  Revenues in the fourth quarter will expand significantly as we fill distributor orders, receive licensing payments, and increase our Altrazeal® business.  Expense continued to be contained and are in line with our financial plan."

Operating ResultsRevenues

Revenue for the third quarter of 2011 was $74,000, compared to $62,000 for the third quarter of 2010.

Revenue for the nine months ended September 30, 2011 was $229,000, compared to $528,000 for the nine months ended September 30, 2010.  The decrease of $299,000 in revenue was due primarily to a decrease of $138,000 in Aphthasol® product sales as we did not sell any Aphthasol® during the first nine months of 2011 and a decrease of $174,000 in Zindaclin® related licensing and royalty fees due to our divestiture of this product in June 2010.

Research and Development

Research and development expenses for the third quarter of 2011 were $233,000, including $17,000 in share-based compensation, compared to $296,000, including $32,000 in share-based compensation, for the third quarter of 2010.  The decrease of approximately $63,000 in research and development expenses was primarily due to lower costs for regulatory fees of $42,000 and share-based compensation of $15,000.

Research and development expenses for the nine months ended September 30, 2011 were $749,000, including $52,000 in share-based compensation, compared to $949,000, including $104,000 in share-based compensation, for the nine months ended September 30, 2010.  The decrease of approximately $200,000 in research and development expenses was primarily due to lower costs for regulatory fees of $133,000, clinical testing costs of $43,000 and scientific compensation costs of $19,000.

Selling, General and Administrative

Selling, general and administrative expenses for the third quarter of 2011 were $566,000, including $25,000 in share-based compensation, compared to $666,000, including $26,000 in share-based compensation, for the third quarter of 2010.  The decrease of approximately $100,000 in selling, general and administrative expenses was primarily due to lower costs for sales & marketing of $135,000 as a result of lower head count, reduced share-based compensation, and decreased marketing expenses.  These expense decreases were partially offset by an increase in shareholder expenses relating to investor relations consulting of $61,000.

Selling, general and administrative expenses for the nine months ended September 30, 2011 were $1.8 million, including $77,000 in share-based compensation, compared to $2.4 million, including $195,000 in share-based compensation, for the nine months ended September 30, 2010.  The decrease of approximately $626,000 in selling, general and administrative expenses was primarily due to lower costs for compensation of $162,000 as a result of lower head count and reduced share-based compensation, sales & marketing costs of $284,000, legal costs relating to our patents of $88,000, commission expense of $30,000 and legal fees of $30,000.  These expense decreases were partially offset by an increase in shareholder expenses of $56,000 relating to investor relations consulting.

Mr. Gray continued, "Significant progress was reported in the third quarter, including financing, a strategic partnership, and clinical data. We achieved an important milestone in the third quarter with the signing of a binding letter of intent for the marketing of Altrazeal® in Europe. Positive clinical data has been produced in Europe in a number of hospitals and key opinion leaders' support is being generated. Plans for producing the initial launch quantities are being developed. This agreement has significant economic benefits to the Company both in the short and longer term. Additionally, further clinical data supporting the use of Altrazeal® in accelerating healing of diabetic foot ulcers was presented at a wound care conference; this is important data as it was in combination with a removable off-loading device which is the major segment of this market. We have also continued our efforts and made advancements towards completing additional partnerships to execute our business plan."

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the anticipated increase in revenues in the fourth quarter of 2011, our business plan for the balance of 2011 including significant revenue growth for our products, the anticipated benefits of our marketing strategy for Altrazeal®, the positive clinical data and key opinion leader support in Europe, and the completion of additional strategic partnerships.  When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the regulatory results for our products.  These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.   These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145ULURU Inc.SUMMARY OF RESULTSSTATEMENTS OF OPERATIONS DATAThree Months Ended September 30,Nine Months Ended September 30,2011201020112010REVENUESLicense fees

$
,184$
4,370$
8,349$  150,283Royalty income

18,86123,10451,528132,473Product sales, net

48,60734,143159,132245,725Other

------------Total Revenues

73,65261,617229,009528,481COSTS AND EXPENSESCost of goods sold

11,0656,41635,545143,259Research and development

233,087295,781749,049948,960Selling, general and administrative

566,541666,2051,779,0452,405,123Amortization of intangible assets

206,454206,454612,632699,252Depreciation

75,35979,073227,665179,053Total Costs and Expenses

1,092,5061,253,9293,403,9364,375,647OPERATING (LOSS)(1,018,854)(1,192,312)(3,174,927)(3,847,166)Other Income (Expense)Interest and miscellaneous income

1,8574,8409,4855,555Interest expense

(22,545)(20,650)(48,839)(37,138)Loss on sale of intangible asset

---------( 857,839)(LOSS) Before Income Taxes(1,039,542)(1,208,122)(3,214,281)(4,736,588)Income taxes

------------NET (LOSS)$(1,039,542)$(1,208,122)$(3,214,281)$(4,736,588)Less preferred stock dividends

(462)---(462)---NET (LOSS) Allocable to Common Stockholders$(1,040,004)$(1,208,122)$(3,214,743)$(4,736,588)Basic and diluted net (loss) per common share

$   (0.18)$   (0.22)$  (0.55)$  (0.87)WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

5,928,0845,472,2885,850,9005,423,076ULURU Inc.SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATASeptember 30, 2011December 31, 2010(Unaudited)(Audited)  Cash and cash equivalents

$
,989$
41,441  Current assets

1,597,4441,996,265  Property and equipment, net

1,147,8181,375,484  Other assets

4,797,0045,648,764  Total assets

7,542,2669,020,513  Current liabilities

1,797,9891,019,597  Long term liabilities

907,994594,653  Total liabilities

2,705,9831,614,250  Total stockholders' equity

4,836,2837,406,263
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Iowa , 11 de fevereiro de 2016 ... inauguração de sua fábrica de soroalbumina bovina (BSA ... Zelândia. A fábrica fica na Ilha Norte da ... "), desenvolvido e estabelecido na fábrica da Proliant ... . O projeto e instalação dos equipamentos ...
(Date:2/11/2016)... INDIANAPOLIS , Feb. 11, 2016 /PRNewswire/ ... people, but for those with type 1 diabetes, the ... students juggle class schedules, assignments and campus activities, they ... 1 diabetes. On top of that, many are living ... Diabetes Scholars Foundation (Foundation) Lilly Diabetes Tomorrow,s Leaders ...
(Date:2/11/2016)... ALBANY, New York , February 11, 2016 ... Research announces the release of a new research report, titled ... Growth, Trends and Forecast, 2013 - 2019". According to the ... expand at a 4.40% CAGR from 2013 to 2019, growing ... bn by 2019. --> --> ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, corporate strategy ... privacy and security law, and best practices in data breaches for the Part ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix today announced that Clive ... be presenting at the 2016 HIMSS Annual Conference & Exhibition, taking place February ... session, “ Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Be Well ... office in the heart of Old Town at 108 South Columbus St, Suite 201, ... the highest level of medical care in the convenience of their homes, offices or ...
(Date:2/11/2016)... Southborough, MA (PRWEB) , ... February 11, 2016 , ... ... avoid overpaying for IT services, what questions to ask your IT consultant before signing ... them access to your computer network. , “With companies relying heavily on e-mail and ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):